Two different orchestras play the same score of damage, but they have different conductors: one brakes before division, the other before DNA replication. Oral cancer and breast cancer receive the same neutron strike, yet respond as if following different conductors. One cell line freezes at the threshold of division, the other at the threshold of copying genetic material. The outcome is the same, cell death, but the path differs.
The researchers took two cancer cell lines: SAS oral squamous cell carcinoma and MCF-7 breast adenocarcinoma. Both were incubated for 24 hours in a solution containing boronophenylalanine, a substance that cells readily take up, and then irradiated at a neutron accelerator for one, two, or three hours. Afterward, they counted DNA breaks, tracked the cell cycle, and checked how many cells could still form progeny.
The difference showed up from the first measurements. SAS cells accumulated roughly three times more boron than MCF-7 cells, and after irradiation their nuclei displayed about 70 fluorescent markers of DNA breaks, compared with 38 in MCF-7. But the main divergence was in the cell cycle. In SAS, the fraction of cells stalled before division rose from 28% to 62% within 24 hours. In MCF-7, nearly 80% of cells halted at an earlier stage, before DNA replication.
The consequences of this halt also diverged. Three days after irradiation, apoptosis, that is, programmed cell death, reached 21% in SAS and 28% in MCF-7. But colony survival, the ability of cells to produce offspring, dropped to 15% in SAS, while in MCF-7 it remained at 47%. In other words, breast cancer cells more often triggered the self-destruct mechanism, yet nearly half of them retained the ability to reproduce. Oral cancer died more quietly, but more reliably.
Before this work, it was unclear how much of the difference in therapy response depended on boron accumulation versus intrinsic cellular programs. Now it is clear that even under the same irradiation regimen, cells choose different strategies. Some brake before division and massively lose reproductive capacity; others stall before DNA replication and slowly enter apoptosis. This means that radiation oncologists should look not only at boron concentration in the tumor but also at its molecular portrait. Two orchestras play the same score, but they have different conductors, and predicting how each will perform requires knowing both.
SAS cells accumulated about three times more boron than MCF-7 (153 µg/L versus 50 µg/L), yet MCF-7 showed higher overall apoptosis by 72 hours, although their colony survival dropped less. This resembles a situation where a louder damage signal does not always mean more reliable cell death.